Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Buy” from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO) has received a consensus rating of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $12.13.

A number of research analysts recently issued reports on STRO shares. Truist Financial reduced their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 16th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research report on Monday. Finally, JMP Securities restated a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research report on Monday.

Institutional Trading of Sutro Biopharma

Several hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Sutro Biopharma in the 4th quarter worth $60,000. ProShare Advisors LLC raised its stake in shares of Sutro Biopharma by 49.1% in the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after buying an additional 5,373 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Sutro Biopharma in the 1st quarter worth $92,000. Price T Rowe Associates Inc. MD raised its stake in shares of Sutro Biopharma by 24.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock worth $102,000 after buying an additional 3,578 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after buying an additional 7,082 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Down 1.5 %

Shares of STRO opened at $3.95 on Friday. The firm has a market cap of $323.09 million, a price-to-earnings ratio of -2.10 and a beta of 1.18. The stock has a 50 day moving average of $4.10 and a 200-day moving average of $4.01. Sutro Biopharma has a 52 week low of $2.01 and a 52 week high of $6.13.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.20. The company had revenue of $25.71 million during the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative return on equity of 102.06% and a negative net margin of 73.48%. On average, sell-side analysts predict that Sutro Biopharma will post -2.96 earnings per share for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.